Sera PrognosticsNovember 4, 2021Sera Prognostics Announces Collaboration to Help Underserved Communities Make Informed Decision about Prenatal Health
Sera PrognosticsSeptember 15, 2021Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Sera PrognosticsAugust 17, 2021Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility
Sera PrognosticsMay 19, 2021Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth
Sera PrognosticsMay 18, 2021Evaluation of Health and Economic Benefit of the PreTRM® Test-And-Treat Strategy to Improve Maternal and Infant Health Among Commercially Insured in the US
Sera PrognosticsFebruary 24, 2020Sera Prognostics to Present at the 40th Annual Cowen Health Care Conference
Sera PrognosticsJanuary 9, 2020Sera Prognostics to Present at the 38th Annual JP Morgan Healthcare Conference
Sera PrognosticsJanuary 9, 2020Data Confirming Performance of Sera Prognostics’s PRETRM® Test to be Presented at the Society for Maternal-Fetal Medicine’s 40th Annual Pregnancy Meeting
Sera PrognosticsJanuary 9, 2020Sera Prognostics Announces Completion of Important Prevent PTB Clinical Intervention Study Using the PRETRM® Test
